分子イメージングの世界市場、市場規模とシェアの分析 - 成長動向と予測（2025年～2033年）

分子イメージング市場の動向とサマリー

世界の分子イメージングの市場規模は、2024年の79億6,000万米ドルから2033年までに123億6,000万米ドルに達すると予測され、2025年～2033年にCAGRで5.01%の成長が見込まれます。これは疾患の早期診断に対する需要の増加、画像診断法の技術革新、分子イメージングが精密診断や個別化治療において重要な役割を果たすがんや神経疾患の罹患率の上昇などによるものです。

分子イメージング市場の成長促進要因

慢性疾患の罹患率の増加

がん、心血管疾患、神経疾患のような慢性疾患の有病率の増加は、分子イメージング産業の主な促進要因です。このような疾患には早期の正確な診断が必要ですが、分子イメージングでは分子・細胞レベルでの生物学的機能の可視化によってそれが可能になります。このような機能により、疾患の検出、病期分類、モニタリングが改善され、患者の転帰が向上し、次世代イメージング技術への需要が高まります。毎年1,800万人が、心臓や血管が侵され、心臓発作や脳卒中、心不全を引き起こす心血管疾患で命を落としています。がんによる死亡者は年間約900万人、喘息やCOPDなどの慢性呼吸器疾患による死亡者は400万人、糖尿病による死亡者は200万人です。しかし、疾病負荷と現代医療へのアクセスは不均衡に配分されています。

画像診断の進歩

PET/CTやPET/MRIのようなハイブリッドイメージングモダリティの導入による画像診断法の継続的な進歩は、診断可能性を一変させました。これらの進歩により、解像度の高い画像が得られ、感度が向上し、より早い段階で疾患を発見できる可能性が出てきました。これらの技術の進歩は診断精度を向上させるだけでなく、個別化医療における分子イメージングの利用を増加させ、市場の成長を後押ししています。2024年6月、Lantheus Holdings, Inc.は、ガストリン放出ペプチド受容体（GRPR）を標的とするLife Molecular ImagingのRM2の全世界での権利取得を報告しました。これらには、臨床段階の放射線治療薬177Lu-DOTA-RM2と放射線診断薬68Ga-DOTA-RM2が含まれます。この買収により、Lantheusは前立腺がんに重点を置き、乳がんやその他のがんにもパイプラインを広げることになります。3,500万ドルの契約一時金に加え、マイルストーン払いとロイヤルティが支払われる可能性があります。

研究開発におけるイノベーション

新たな造影剤を特定し、現行のイメージング手法を強化するための研究開発プロセスへの高額な出資が進行中です。このことはより効率的な診断法や治療法の開発につながるため、分子イメージングの発展に不可欠です。研究開発への注力は、市場の成長を支え、臨床ニーズのギャップを埋める新しいソリューションの流れをもたらします。America College of Radiologyによると、大統領の2024年度予算には、National Cancer Institute（NCI）に対する裁量予算が大幅に増額され、2023年度の割り当てから5億米ドル増の7億1,600万米ドルとなっています。この資金は、研究、予防、診断、治療への取り組みを推進するために使用されますが、これらはすべて放射線学とイメージング技術に大きく依存しています。

分子イメージング市場の課題

イメージング装置と手技の高いコスト

先進の分子イメージング装置や手技の高いコストが市場の拡大の大きな障害となっています。特に発展途上国や小規模な医療センターでは、高額な取得費や維持費がこれらの技術の使用を制限しています。また、造影剤のコストや熟練者の必要性も経営費を押し上げ、普及を妨げています。

規制と償還の課題

分子イメージング手技の複雑な規制環境への対応と償還の獲得は依然として困難です。厳しい規制環境は、新しい造影剤と装置の承認や商業化を阻む可能性があります。さらに、地域によって異なる償還政策が、分子イメージングサービスの利用可能性とコストに影響を与え、市場浸透に影響を与える可能性があります。

当レポートでは、世界の分子イメージング市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 分子イメージング市場

• 過去の市場動向
• 市場予測

第6章 分子イメージングの市場シェア分析

• モダリティ別
• 用途別
• 最終用途別
• 国別

第7章 モダリティ

• 単一光子放射断層撮影（SPECT）
• 陽電子放射断層撮影（PET）
• 核磁気共鳴分光計
• 分子超音波イメージング
• その他

第8章 用途

• 腫瘍
• 心血管
• 神経
• 呼吸器
• 消化器

第9章 最終用途

• 病院
• 画像診断センター
• 研究機関

第10章 国

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • オーストラリア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 ポーターのファイブフォース分析

第12章 SWOT分析

第13章 主要企業の分析

• GE HealthCare
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Shimadzu Corp
• United Imaging Healthcare Co., Ltd.
• Bruker Corp
• FUJIFILM Holdings Corp
• Cubresa Inc.

Molecular Imaging Market Trends & Summary

The Molecular Imaging Market is anticipated to grow to US$ 12.36 billion by 2033 from US$ 7.96 billion in 2024, at a CAGR of 5.01% during the period from 2025 to 2033. This is fueled by increasing demand for early disease diagnosis, technological innovations in imaging modalities, and rising incidence of cancer and neurological diseases, where molecular imaging plays a critical role in precision diagnosis and personalized treatment.

The report Molecular Imaging Market & Forecast covers by Modality (Single Photon Emission Computed Tomography, Psitron Emmission Tomography, Nuclear Magnetic Resonance Spectrometer, Molecular Ultrasound Imaging, Others), Application (Oncology, Cardiovascular, Neurology, Respiratory, Gastrointestinal), End Use (Hospitals, Diagnostic Imaging Centers, Research Institutes), Country and Company 2025-2033.

Molecular Imaging Market Outlooks

Molecular imaging is a cutting-edge biomedical technology that facilitates visualization, characterization, and measurement of biological functions at the molecular and cellular level within living systems. In contrast to conventional imaging technologies that merely concentrate on anatomical structures, molecular imaging yields extensive information regarding how tissues and organs work in real-time. It integrates imaging modalities like positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and optical imaging with molecular probes or biomarkers.

Molecular imaging is essential in the early disease detection and follow-up of conditions like cancer, cardiovascular disease, and neurological diseases like Alzheimer's and Parkinson's disease. It assists in assessing the effectiveness of a treatment by monitoring biological reactions at the molecular level. It also assists in drug discovery since researchers can monitor how new drugs interact with biological targets in living organisms. Its non-invasive character and capability to deliver accurate, functional information make molecular imaging a pillar of personalized medicine.

Growth Drivers in the Molecular Imaging Market

Increased Incidence of Chronic Diseases

The growing prevalence of chronic diseases like cancer, cardiovascular disease, and neurological conditions is a key growth driver for the molecular imaging industry. Such diseases require early and precise diagnosis, which molecular imaging makes possible through the visualization of biological functions at the molecular and cellular levels. Such a capability improves the detection, staging, and monitoring of disease, improving patient outcomes and driving demand for next-generation imaging technology. Every year 18 million individuals succumb to cardiovascular diseases that involve the heart and blood vessels and can result in heart attacks, stroke, or heart failure. Approximately 9 million individuals die annually from cancers, 4 million from chronic respiratory diseases like asthma or COPD, and 2 million from diabetes. But both disease burden and access to contemporary health care are disproportionately allocated.

Advances in Imaging Modalities

Ongoing advances in imaging modalities, with the introduction of hybrid imaging modalities such as PET/CT and PET/MRI, have transformed diagnostic potential. These advances provide images with greater resolution, increased sensitivity, and the potential to detect illnesses at earlier stages. These technological advances not only improve diagnostic precision but also increase the utilization of molecular imaging in personalized medicine, thus boosting market growth. June 2024, Lantheus Holdings, Inc. reported its acquisition of worldwide rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR). These include the clinical-stage radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2. The acquisition strengthens Lantheus' emphasis on prostate cancer and broadens its pipeline to breast and other cancers, with an upfront payment of $35 million plus possible milestone payments and royalties.

Innovation in Research and Development

Higher expenditure in research and development processes to identify new imaging agents and enhance current imaging methods is underway. It is vital for the development of molecular imaging, as it results in the creation of more efficient diagnostic methods and treatments. The focus on R&D provides a stream of new solutions, which supports growth in the market and fills gaps in clinical need. As per the America College of Radiology, The president's 2024 budget included a substantial increase in discretionary funding for the National Cancer Institute (NCI) to USD 716 million, a USD 500 million increase from the FY 2023 allocation. The funds are to be used to advance research, prevention, diagnosis, and treatment efforts, all of which rely extensively on radiology and imaging technology.

Challenges in the Molecular Imaging Market

High Cost of Imaging Equipment and Procedures

The high cost of advanced molecular imaging equipment and procedures is a major hindrance to market expansion. High acquisition and maintenance expenses restrict the use of these technologies, especially in developing countries and small healthcare centers. The cost of imaging agents and the requirement for skilled personnel also drive up operational costs, preventing widespread adoption.

Regulatory and Reimbursement Challenges

Working with the intricate regulatory environment and gaining reimbursement for molecular imaging procedures is still difficult. The strict regulatory environment can hold up the approval and commercialization of new imaging agents and devices. In addition, variable reimbursement policies between different regions can impact the availability and cost of molecular imaging services, which can influence market penetration.

Molecular Ultrasound Imaging Market

Molecular ultrasound imaging integrates conventional ultrasound methods with targeted contrast agents to image particular molecular markers in the body. Molecular ultrasound imaging is a non-invasive technique with real-time imaging and high spatial resolution, and it is worth its weight in gold for early disease detection and monitoring therapeutic interventions. Its low cost of entry and favorable safety profile over other imaging modalities make it increasingly popular in the clinical environment.

Oncology Molecular Imaging Market

In cancer, molecular imaging is a central component of early detection, staging, and monitoring of cancer. Modalities such as PET and SPECT allow visualization of tumor metabolism and receptor expression and thus insight into tumor biology. Such information is invaluable for choosing the right therapies, evaluating treatment response, and detecting recurrences, thus enhancing patient management and outcomes.

Neurology Molecular Imaging Market

Molecular imaging plays a crucial role in diagnosing and managing neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. By visualizing distinct neurotransmitter systems and pathological protein accumulations, these imaging techniques enable early diagnosis and monitoring of disease progression. This ability fosters a greater understanding of neurological disease and aids in the creation of targeted therapeutics.

Respiratory Molecular Imaging Market

Molecular imaging is supporting the evaluation of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer in respiratory medicine. Molecular imaging helps in imaging inflammatory processes, ventilation-perfusion mismatches, and tumor metabolism. All of this information guides clinicians to tailor treatment regimens, follow the therapeutic responses, and enhance the outcomes of the patients.

Molecular Imaging Hospitals Market

Hospitals are the first adopters of molecular imaging technologies because of their complete diagnostic and therapeutic facilities. Incorporation of molecular imaging in hospitals improves diagnostic accuracy, informs treatment planning, and enables personalized medicine strategies. Multidisciplinary teams and advanced infrastructure available in hospitals enable effective use of these imaging modalities.

Molecular Imaging in Research Institutes

Research institutes utilize molecular imaging to study mechanisms of disease, assess emerging treatments, and generate new imaging probes. The institutes are significant players in expanding the field by engaging in preclinical and clinical investigations that directly guide clinical care. Research institutes working together with industry partners are at the heart of driving innovation and shaping advances in molecular imaging technology.

United States Molecular Imaging Market

The United States is a large market for molecular imaging, with high incidence of chronic diseases, sophisticated healthcare infrastructure, and high research and development investment. The availability of top imaging technology firms and academic institutions encourages innovation and uptake of advanced imaging modalities. Favorable regulatory environments and reimbursement policies also encourage market growth. November 2024, United Imaging installed the world's first uMI Panvivo PET/CT at Pueblo Medical Imaging in Nevada, USA. The next-generation platform boasts a best-in-class NEMA spatial resolution of 2.9 mm* and an effective sensitivity of 181 cps/kBq. Equipped with its AI-based 3D camera technology, the uMI Panvivo brings precision and care to all.

Germany Molecular Imaging Market

Germany's molecular imaging market is marked by strong healthcare infrastructure, high focus on medical research, and positive reimbursement policies. The precision medicine and early disease detection focus of the country facilitates the uptake of advanced imaging technologies. Academic-industry collaborations help in the development and deployment of innovative imaging solutions. United Imaging has deployed its innovative molecular imaging technology in Germany, partnering with Medical Imaging Electronics (MiE). The Kliniken Essen-Mitte Evang and Nukmed are now equipped with the uMI 550 digital PET/CT system, a cutting-edge system.

India Molecular Imaging Market

The molecular imaging market in India is growing, supported by growing healthcare consciousness, rising chronic disease incidence, and increasing investments in healthcare infrastructure. Government policies promoting diagnostic ability and access to advanced medical technologies are driving market expansion. The emergence of affordable imaging solutions optimized for the Indian populace is also driving market growth. May 2025, Mahajan Imaging & Labs has inaugurated North India's first 128-Slice Digital PET-CT - Omni Legend by GE HealthCare, along with a state-of-the-art pathology lab in Gurugram. This new center is a major step forward in integrated cancer care and diagnostics for Delhi NCR.

Saudi Arabia Molecular Imaging Market

Saudi Arabia is experiencing growth in the molecular imaging market because of the increasing burden of chronic diseases, government investment in healthcare modernization, and initiatives to improve diagnostic capabilities. The Vision 2030 initiative of the country focuses on the development of sophisticated healthcare services, including the implementation of cutting-edge imaging technologies. Partnerships with global players and investments in health infrastructure facilitate the growth of the market. December 2024, King Abdulaziz University (KAU) has initiated a groundbreaking Alzheimer's disease diagnosis service at its Molecular Imaging Center (I-One) via Wadi Jeddah. This service is provided using combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI), making it the first of its nature in Saudi Arabia.

Molecular Imaging Market Segmentation

Modality

• Single Photon Emission Computed Tomography
• Psitron Emmission Tomography
• Nuclear Magnetic Resonance Spectrometer
• Molecular Utrasound Imaging
• Others

Application

• Oncology
• Cardiovascular
• Neurology
• Respiratory
• Gastrointestinal

End Use

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All companies have been covered with 4 Viewpoints

• Overview
• Key Persons
• Recent Development & Strategies
• Revenue Analysis

Key Players Analysis

• GE HealthCare
• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Shimadzu Corp
• United Imaging Healthcare Co., Ltd.
• Bruker Corp
• FUJIFILM Holdings Corp
• Cubresa Inc.

Table of Contents

1. Introduction

2. Research Methodology

• 2.1 Data Source
  • 2.1.1 Primary Sources
  • 2.1.2 Secondary Sources
• 2.2 Research Approach
  • 2.2.1 Top-Down Approach
  • 2.2.2 Bottom-Up Approach
• 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Molecular Imaging Market

• 5.1 Historical Market Trends
• 5.2 Market Forecast

6. Molecular Imaging Market Share Analysis

• 6.1 By Modality
• 6.2 By Application
• 6.3 By End Use
• 6.4 By Countries

7. Modality

• 7.1 Single Photon Emission Computed Tomography
• 7.2 Psitron Emmission Tomography
• 7.3 Nuclear Magnetic Resonance Spectrometer
• 7.4 Molecular Utrasound Imaging
• 7.5 Others

8. Application

• 8.1 Oncology
• 8.2 Cardiovascular
• 8.3 Neurology
• 8.4 Respiratory
• 8.5 Gastrointestinal

9. End Use

• 9.1 Hospitals
• 9.2 Diagnostic Imaging Centers
• 9.3 Research Institutes

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Thailand
  • 10.3.6 Malaysia
  • 10.3.7 Indonesia
  • 10.3.8 Australia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 Saudi Arabia
  • 10.5.2 UAE
  • 10.5.3 South Africa

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 GE HealthCare
  • 13.1.1 Overview
  • 13.1.2 Key Persons
  • 13.1.3 Recent Development & Strategies
  • 13.1.4 Revenue Analysis
• 13.2 Siemens Healthineers AG
  • 13.2.1 Overview
  • 13.2.2 Key Persons
  • 13.2.3 Recent Development & Strategies
  • 13.2.4 Revenue Analysis
• 13.3 Koninklijke Philips N.V.
  • 13.3.1 Overview
  • 13.3.2 Key Persons
  • 13.3.3 Recent Development & Strategies
  • 13.3.4 Revenue Analysis
• 13.4 Shimadzu Corp
  • 13.4.1 Overview
  • 13.4.2 Key Persons
  • 13.4.3 Recent Development & Strategies
  • 13.4.4 Revenue Analysis
• 13.5 United Imaging Healthcare Co., Ltd.
  • 13.5.1 Overview
  • 13.5.2 Key Persons
  • 13.5.3 Recent Development & Strategies
  • 13.5.4 Revenue Analysis
• 13.6 Bruker Corp
  • 13.6.1 Overview
  • 13.6.2 Key Persons
  • 13.6.3 Recent Development & Strategies
  • 13.6.4 Revenue Analysis
• 13.7 FUJIFILM Holdings Corp
  • 13.7.1 Overview
  • 13.7.2 Key Persons
  • 13.7.3 Recent Development & Strategies
  • 13.7.4 Revenue Analysis
• 13.8 Cubresa Inc.
  • 13.8.1 Overview
  • 13.8.2 Key Persons
  • 13.8.3 Recent Development & Strategies